.1 Stefani M, Dobson CM. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. Journal of molecular medicine. 2003;81(11):678-99.
.2 Bouchard M, Zurdo J, Nettleton EJ, Dobson CM, Robinson CV. Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Science. 2000;9(10):1960-7.
.3 Sunde M, Blake CC. From the globular to the fibrous state: protein structure and structural conversion in amyloid formation. Quarterly reviews of biophysics. 1998;31(01):1-39.
.4 LeVine 3rd H. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein science: a publication of the Protein Society. 1993;2(3):404.
.5 Collins SR, Douglass A, Vale RD, Weissman JS. Mechanism of prion propagation: amyloid growth occurs by monomer addition. PLoS biology. 2004;2:1582-90.
.6 Bellotti V, Chiti F. Amyloidogenesis in its biological environment: challenging a fundamental issue in protein misfolding diseases. Current opinion in structural biology. 2008;18(6):771-9.
.7 Forno LS. Neuropathology of Parkinson's disease. Journal of Neuropathology & Experimental Neurology. 1996;55(3):259-72.
.8 Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proceedings of the National Academy of Sciences. 1998;95(11):6469-73.
.9 Iwai A, Yoshimoto M, Masliah E, Saitoh T. Non-A. beta. Component of Alzheimer's Disease Amyloid (NAC) is Amyloidogenic. Biochemistry. 1995;34(32):10139-45.
.10 Justine R, Maria-Grazia M. Considerations for the Use of Polyphenols as Therapies in Neurodegenerative Diseases. Considerations for the Use of Polyphenols as Therapies in Neurodegenerative Diseases. 2019, 20, 1883:.10.3390
11. Mészáros A, Muwonge K, Janvier S, Ahmed J, Tompa P. A Novel Tandem-Tag Purification Strategy for Challenging Disordered Proteins. Biomolecules. 2022 Oct 26;12(11):1566.
12. Xiao‑Feng Z, Guo‑Qiang T, Wu W. A simple and rapid protein purification method based on cell-surface display of SUMO-fused recombinant protein and Ulp1 protease.
.13 Tauseef R. B, Suzanne C. E, John P. H, Michael R. M. SUMO fusion technology for diYcult-to-express proteins. 10.1016/j.pep.2005.03.016
.14 Huiyan W, Yechen X, Lianjun F, Hongxin Z, Yaofang Z, Xiaoshan W, Yuxia Q,Yadong H, Hongchang G, Xiaokun L. High-level expression and purification of soluble recombinant FGF21 protein by SUMO fusion in Escherichia coli. 2010, 10:14/1472-6750/10/14
15. Petranka K, Erik M, Manuel G, Marilyn T, He-Hsuan H, Guillaume B, Henning U, Markus Z, Sebastian K, Frauke M, Mathias B, Jochen H. W. Sumoylation inhibits α-synuclein aggregation
and toxicity. 201010117:. 10.1083
16. Savyon M, Engelender S. SUMOylation in α-synuclein homeostasis and pathology. Frontiers in Aging Neuroscience. 2020 Jun 25;12:167.
17. Yu-Qian Z, Kevin D. S. Sumoylation of amyloid precursor protein negatively regulates
Aβ aggregate levels. 2008 , 3; 374(4): 673–678
